Literature DB >> 7816531

Very immature infants (< or = 30 Wk) respond to glucose infusion with incomplete suppression of glucose production.

A Sunehag1, J Gustafsson, U Ewald.   

Abstract

Small substrate stores and immature enzyme systems make preterm infants prone to develop hypoglycemia. Hyperglycemia may also occur, particularly when these infants are given i.v. glucose. To evaluate the capacity for regulation of glucose production in response to glucose infusion, 10 newborn infants, born after 25-30 wk of gestation, were studied. Their glucose production rates (GPR) were calculated and the concentrations of glucose, insulin, and glucagon in plasma were measured during infusion of glucose at a rate of first 1.7 +/- 0.2 and then 6.5 +/- 0.3 mg.kg-1.min-1 (9.4 +/- 1.1 and 36.1 +/- 1.7 mumol.kg-1.min-1) (mean +/- SD). GPR was determined by use of D-6,6-2H2-glucose. When the rate of infusion of glucose was increased, GPR decreased from 4.3 +/- 1.3 to 1.4 +/- 1.1 mg.kg-1.min-1 (23.9 +/- 7.2 to 7.8 +/- 6.1 mumol.kg-1.min-1) (mean +/- SD) (p = 0.00006). In addition, the plasma insulin concentration increased from 6 +/- 2 to 11 +/- 4 microU.mL-1 (p = 0.006) and the plasma glucose concentration from 3.6 +/- 1.1 to 6.1 +/- 1.3 mM (mean +/- SD) (p = 0.0002), whereas the glucagon concentration remained unchanged. Only the insulin concentration in plasma was significantly related to GPR. The results show that very immature newborn infants have an incomplete and varying capacity to respond to glucose infusion with suppression of glucose production. Insulin seems to be more important than plasma glucose in the regulation of glucose homeostasis in these infants.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7816531     DOI: 10.1203/00006450-199410000-00024

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

Review 1.  Hypoglycaemia of the newborn: a review.

Authors:  A F Williams
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

2.  Chronic parenteral nutrition induces hepatic inflammation, steatosis, and insulin resistance in neonatal pigs.

Authors:  Barbara Stoll; David A Horst; Liwei Cui; Xiaoyan Chang; Kenneth J Ellis; Darryl L Hadsell; Agus Suryawan; Ashish Kurundkar; Akhil Maheshwari; Teresa A Davis; Douglas G Burrin
Journal:  J Nutr       Date:  2010-10-27       Impact factor: 4.798

3.  Continuous parenteral and enteral nutrition induces metabolic dysfunction in neonatal pigs.

Authors:  Barbara Stoll; Patrycja Jolanta Puiman; Liwei Cui; Xiaoyan Chang; Nancy Marie Benight; Caroline Bauchart-Thevret; Bolette Hartmann; Jens Juul Holst; Douglas Guy Burrin
Journal:  JPEN J Parenter Enteral Nutr       Date:  2012-05-01       Impact factor: 4.016

4.  Gluconeogenesis is not regulated by either glucose or insulin in extremely low birth weight infants receiving total parenteral nutrition.

Authors:  Shaji K Chacko; Jorge Ordonez; Pieter J J Sauer; Agneta L Sunehag
Journal:  J Pediatr       Date:  2011-02-15       Impact factor: 4.406

Review 5.  Glucagon, cyclic AMP, and hepatic glucose mobilization: A half-century of uncertainty.

Authors:  Robert L Rodgers
Journal:  Physiol Rep       Date:  2022-05

Review 6.  On the problem of patient-specific endogenous glucose production in neonates on stochastic targeted glycemic control.

Authors:  Jennifer L Dickson; James N Hewett; Cameron A Gunn; Adrienne Lynn; Geoffrey M Shaw; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2013-07-01

7.  Characterization of short- and long-term morbidity and mortality of goat kids born to does with pregnancy toxemia.

Authors:  Leslie F Weaver; Melanie J Boileau; Lyndi L Gilliam; Jared D Taylor
Journal:  J Vet Intern Med       Date:  2021-02-26       Impact factor: 3.333

8.  Hyperglycaemic preterm neonates exhibit insulin resistance and low insulin production.

Authors:  Emma R Salis; David M Reith; Benjamin J Wheeler; Roland S Broadbent; Natalie J Medlicott
Journal:  BMJ Paediatr Open       Date:  2017-09-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.